Adv Sci (Weinh)

1. PENG L, Zhao A, Li R, Liu Y, et al
   Self-Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for Enhanced Bladder Cancer Immunotherapy.
   Adv Sci (Weinh). 2025 Mar 26:e2502750. doi: 10.1002/advs.202502750.
   

   >> Share

   
   

   
   Am J Clin Exp Urol

2. QI T, He F, Wu S, Wang Q, et al
   2'-Hydroxyflavanone inhibits bladder cancer cell proliferation and angiogenesis via regulating miR-99a-5p/mTOR signaling.
   Am J Clin Exp Urol. 2025;13:20-32.
   

   >> Share

   
   

   
   Am J Pathol

3. TENG F, Zhang R, Wang Y, Li Q, et al
   Machine Learning and Mendelian Randomization Reveal a Tumor Immune Cell Profile for Predicting Bladder Cancer Risk and Immunotherapy Outcomes.
   Am J Pathol. 2025 Mar 21:S0002-9440(25)00077.
   

   >> Share

   
   

   
   Apoptosis

4. SAINI D, Chaudhary PK, Chaudhary JK, Kaur H, et al
   Molecular mechanisms of antiproliferative and pro-apoptotic effects of essential oil active constituents in MCF7 and T24 cancer cell lines: in vitro insights and in silico modelling of proapoptotic gene product-compound interactions.
   Apoptosis. 2025;30.
   

   >> Share

   
   

   
   Arch Pathol Lab Med

5. COELHO KMPA, Fronza H Jr, Carvalho P, Tagliari GB, et al
   Effects of the Paris System on the Unsatisfactory Category in a Cytohistologic Correlation Study of Patients With Urothelial Carcinoma.
   Arch Pathol Lab Med. 2025;149:368-371.
   

   >> Share

   
   

   
   Biology (Basel)

6. NALKIRAN I, Sevim Nalkiran H
   Repurposing ProTAME for Bladder Cancer: A Combined Therapeutic Approach Targeting Cell Migration and MMP Regulation.
   Biology (Basel). 2025;14:263.
   

   >> Share

   
   

   
   Biomedicines

7. PEREZ M, Lozano JJ, Ingelmo-Torres M, Domenech M, et al
   Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer.
   Biomedicines. 2025;13:740.
   

   >> Share

   
   
8. KAST RE
   UBC4: A Repurposed Drug Regimen for Adjunctive Use During Bladder Cancer Treatment.
   Biomedicines. 2025;13:706.
   

   >> Share

   
   
9. TOBISAWA Y, Nakane K, Koie T, Taniguchi T, et al
   Low GCNT2/I-Branching Glycan Expression Is Associated with Bladder Cancer Aggressiveness.
   Biomedicines. 2025;13:682.
   

   >> Share

   
   

   
   BJU Int

10. TREVISANI F, Floris M, Longoni M, Rosiello G, et al
    Acute kidney disease after radical cystectomy for bladder cancer: a new onco-nephrological view.
    BJU Int. 2025 Mar 21. doi: 10.1111/bju.16696.
    

    >> Share

    
    
11. COLLETT G, Bashford T, Whitehead NJ, Kazimierska E, et al
    Occupational incidence of bladder cancer amongst veteran ammunition technicians of the British Army.
    BJU Int. 2025 Mar 22. doi: 10.1111/bju.16678.
    

    >> Share

    
    

    
    Bladder Cancer

12. MESSING EM
    Standard vs extended lymphadenectomy for muscle invasive bladder cancer.
    Bladder Cancer. 2025;11:23523735251314984.
    

    >> Share

    
    

    
    BMC Cancer

13. DAI L, Ye K, Yao G, Lin J, et al
    Using machine learning for predicting cancer-specific mortality in bladder cancer patients undergoing radical cystectomy: a SEER-based study.
    BMC Cancer. 2025;25:523.
    

    >> Share

    
    
14. WAN S, Li KP, Chen SY, Wang CY, et al
    Single-cell sequencing combined with urinary multi-omics analysis reveals that the non-invasive biomarker PRDX5 regulates bladder cancer progression through ferroptosis signaling.
    BMC Cancer. 2025;25:533.
    

    >> Share

    
    
15. YANG H, Zhang T, Li Z, Cai Y, et al
    Risk factors for in-hospital venous thromboembolism in patients with bladder cancer: A retrospective single-center study.
    BMC Cancer. 2025;25:536.
    

    >> Share

    
    

    
    BMJ Case Rep

16. ZENGER M, Zellweger T, Belenyesi Z, Kurz M, et al
    Urogenital infection with M. bovis BCG most probably as a result of BCG instillation 21 years ago.
    BMJ Case Rep. 2025;18:e260496.
    

    >> Share

    
    

    
    Cancer Med

17. GAO Z, Zhang L, Li Z, Qin X, et al
    Visceral Adipose Predicts Prognosis and Toxicities in Locally Advanced Bladder Cancer Patients Treated With Adjuvant Gemcitabine Plus Cisplatin Chemotherapy.
    Cancer Med. 2025;14:e70742.
    

    >> Share

    
    

    
    Cancer Res

18. YU Y, Gao X, Zhao H, Sun J, et al
    A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer.
    Cancer Res. 2025 Mar 24. doi: 10.1158/0008-5472.CAN-24-3217.
    

    >> Share

    
    

    
    Cell Biosci

19. WANG T, Guo T, Sun J, Zang X, et al
    Loss of OBSCN expression promotes bladder cancer progression but enhances the efficacy of PD-L1 inhibitors.
    Cell Biosci. 2025;15:40.
    

    >> Share

    
    

    
    Cell Death Dis

20. SUN N, Wang S, Liu J, Zhang P, et al
    XIAP promotes metastasis of bladder cancer cells by ubiquitylating YTHDC1.
    Cell Death Dis. 2025;16:205.
    

    >> Share

    
    

    
    Clin Radiol

21. SELVARAJU A, Patbamniya NK, Kumar M, Seth A, et al
    Preoperative prediction of muscle invasion in bladder cancer in the Indian population using the Vesical Imaging-Reporting and Data System (VI-RADS) score and individual multiparametric magnetic resonance imaging (MRI) characteristics.
    Clin Radiol. 2025;84:106862.
    

    >> Share

    
    

    
    Curr Issues Mol Biol

22. LIU C, Deng Y, Huang L, Nie X, et al
    USP5 Suppresses Ferroptosis in Bladder Cancer Through Stabilization of GPX4.
    Curr Issues Mol Biol. 2025;47:211.
    

    >> Share

    
    

    
    Cytojournal

23. LI J, Lv Y, Xue S, Li W, et al
    Ailanthone inhibits bladder cancer tumor and cell proliferation, epithelial-mesenchymal transition, and activation of the Janus kinase/signal transducer and activator of transcription 3 signaling pathway.
    Cytojournal. 2025;22:16.
    

    >> Share

    
    

    
    Cytokine

24. LIN F, Hu S, Chen J, Li H, et al
    MiR-125b suppresses bladder Cancer cell growth and triggers apoptosis by regulating IL-6/IL-6R/STAT3 axis in vitro and in vivo.
    Cytokine. 2025;190:156926.
    

    >> Share

    
    

    
    Discov Oncol

25. LENG X, Chen H, Chen G
    Construction and validation of a reliable disulfidptosis-related lncRNAs signature of the subtype, prognostic, and immune landscape in bladder cancer.
    Discov Oncol. 2025;16:418.
    

    >> Share

    
    
26. ZUO J, Chen J, Tan Z, Zhu X, et al
    Analysis of long-term trends and 15-year predictions of smoking-related bladder cancer burden in china across different age and sex groups from 1990 to 2021.
    Discov Oncol. 2025;16:408.
    

    >> Share

    
    

    
    Eur J Med Res

27. WANG J, Yang L, Du S, Pan Y, et al
    Correlation between thyroid hormone levels and the incidence and staging of bladder cancer.
    Eur J Med Res. 2025;30:211.
    

    >> Share

    
    

    
    Eur Urol

28. YU M, Goel A, Tura B, Whalley CM, et al
    Towards Epigenetic-based Subtyping of Bladder Cancer: DNA Methylation Predicts Molecular Subtypes of Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Mar 7:S0302-2838(25)00126-5. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    

    
    Eur Urol Oncol

29. AFFERI L, Gallioli A, Stracci D, Mattei A, et al
    Lights and Shadows of Bacillus Calmette-Guerin (BCG)-exposed and BCG-unresponsive Definitions: A Practical Overview.
    Eur Urol Oncol. 2025;8:231-233.
    

    >> Share

    
    
30. BENJAMIN DJ, Kalebasty AR
    Pairing the Right Individual with the Right Regimen: Patient Selection Criteria in the Treatment of Advanced Urothelial Carcinoma.
    Eur Urol Oncol. 2025;8:237-238.
    

    >> Share

    
    
31. BASILE G, Uleri A, Leni R, Cannoletta D, et al
    En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis of Oncological, Histopathological, and Surgical Outcomes.
    Eur Urol Oncol. 2025;8:520-533.
    

    >> Share

    
    
32. BARTHELEMY P, Thibault C, Flechon A, Gross-Goupil M, et al
    Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment.
    Eur Urol Oncol. 2025;8:407-416.
    

    >> Share

    
    
33. JINDAL T, Jiang C, Alhalabi O, Nizam A, et al
    Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
    Eur Urol Oncol. 2025;8:258-262.
    

    >> Share

    
    
34. BENJAMIN DJ, Rezazadeh Kalebasty A, Mar N
    Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for Treating Advanced Urothelial Carcinoma.
    Eur Urol Oncol. 2025;8:242-244.
    

    >> Share

    
    

    
    Explor Target Antitumor Ther

35. GODLEWSKI D, Bartusik-Aebisher D, Czech S, Szpara J, et al
    Bladder cancer biomarkers.
    Explor Target Antitumor Ther. 2025;6:1002301.
    

    >> Share

    
    

    
    Front Cell Infect Microbiol

36. BOBAN T, Milic Roje B, Knezovic D, Jeroncic A, et al
    Urinary microbiota changes among NMIBC patients during BCG therapy: comparing BCG responders and non-responders.
    Front Cell Infect Microbiol. 2025;15:1479795.
    

    >> Share

    
    

    
    Indian J Clin Biochem

37. SINGH V, Singh MK, Kumar A, Sahu DK, et al
    Metabolomic Biomarkers for Prognosis in Non-Muscle Invasive Bladder Cancer: A Comprehensive Systematic Review and Meta-Analysis.
    Indian J Clin Biochem. 2025;40:176-190.
    

    >> Share

    
    

    
    Int Immunopharmacol

38. CHENG Y, Sun Q, Chen Y, Wang J, et al
    DTX3 suppresses bladder cancer cell invasion and metastasis by inhibiting the Notch signaling pathway.
    Int Immunopharmacol. 2025;153:114529.
    

    >> Share

    
    

    
    Int J Clin Oncol

39. UCHIMOTO T, Iwatsuki K, Komura K, Fukuokaya W, et al
    Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium.
    Int J Clin Oncol. 2025;30:761-769.
    

    >> Share

    
    

    
    Int J Urol

40. SANO T, Ohe C, Nakamoto T, Yoshida T, et al
    Pathological Analysis of False-Positive Samples in Photodynamic Diagnosis of Bladder Cancer According to a History of Intravesical Bacillus Calmette-Guerin Therapy.
    Int J Urol. 2025 Mar 26. doi: 10.1111/iju.70045.
    

    >> Share

    
    

    
    Int Wound J

41. 
    RETRACTION: Impacts of Enhanced Recovery After Surgery Nursing Interventions on Wound Infection and Complications Following Bladder Cancer Surgery: A Meta-Analysis.
    Int Wound J. 2025;22:e70449.
    

    >> Share

    
    

    
    J Clin Med

42. KUS F, Guven DC, Yildirim HC, Chalabiyev E, et al
    Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score.
    J Clin Med. 2025;14:1954.
    

    >> Share

    
    
43. CIANFLONE F, Tartara A, Aretano L, Da Prat V, et al
    Effect of Perioperative Immunonutrition on Early-Postoperative Complications in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Case Series.
    J Clin Med. 2025;14:1992.
    

    >> Share

    
    

    
    J Endocrinol Invest

44. JIANG J, Pang Y, Luo R, Wei Y, et al
    Genetics of urinary bladder paragangliomas: a multi-center study of a Chinese cohort.
    J Endocrinol Invest. 2025;48:931-939.
    

    >> Share

    
    

    
    J Patient Rep Outcomes

45. RUTHERFORD C, Tait MA, Costa DSJ, King MT, et al
    Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SI.
    J Patient Rep Outcomes. 2025;9:36.
    

    >> Share

    
    

    
    J Robot Surg

46. FAN G, Ma J, Wu Y, Wang J, et al
    Robotic versus open surgery for ureteroenteric stricture after radical cystectomy: a systematic review and meta-analysis.
    J Robot Surg. 2025;19:130.
    

    >> Share

    
    

    
    J Transl Med

47. WAHAFU W, Zhou Q, Yang X, Yang Y, et al
    Spatial relationships and interactions of immune cell niches are linked to the pathologic response of muscle-invasive bladder cancer to neoadjuvant therapy.
    J Transl Med. 2025;23:375.
    

    >> Share

    
    

    
    J Urol

48. KAMAT AM, van Rhijn BWG, Van der Kwast T
    Hybrid 3-Tier Bladder Cancer Grade: The Mutually Beneficial Marriage Of Two Grading Systems.
    J Urol. 2025 Mar 25:101097JU0000000000004542. doi: 10.1097/JU.0000000000004542.
    

    >> Share

    
    

    
    Medicina (Kaunas)

49. BARKAY O, Keskin E
    Intravesical BCG: A Double-Edged Sword? The Untold Story of Infection Risks.
    Medicina (Kaunas). 2025;61:379.
    

    >> Share

    
    
50. NESIU A, Novacescu D, Latcu S, Bardan R, et al
    Diagnostic Performance and Interobserver Agreement of the Vesical Imaging-Reporting and Data System (VI-RADS) in Bladder Cancer Staging: A Systematic Review.
    Medicina (Kaunas). 2025;61:469.
    

    >> Share

    
    

    
    Medicine (Baltimore)

51. GONG Z, Liu Z, Zhu J, Zhao Z, et al
    Global research trends and hotspots on imaging of bladder cancer: A bibliometric and visual analysis from 1981 to 2023.
    Medicine (Baltimore). 2025;104:e41907.
    

    >> Share

    
    

    
    Mol Biol Rep

52. SAIDANI B, Boubaker NS, Chakroun M, Ayed H, et al
    FGFR3 gene mutations screening in non-muscle invasive bladder cancer (NMIBC) in the Tunisian population.
    Mol Biol Rep. 2025;52:338.
    

    >> Share

    
    
53. SINGH R, Singh UP, Agrawal V, Garg M, et al
    Retraction Note: Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
    Mol Biol Rep. 2025;52:334.
    

    >> Share

    
    

    
    Naunyn Schmiedebergs Arch Pharmacol

54. SAADH MJ, Hussein WS, Al-Hussainy AF, Bishoyi AK, et al
    Circular RNAs: driving forces behind chemoresistance and immune evasion in bladder cancer.
    Naunyn Schmiedebergs Arch Pharmacol. 2025.
    

    >> Share

    
    

    
    NPJ Digit Med

55. BAI Z, Osman M, Brendel M, Tangen CM, et al
    Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning.
    NPJ Digit Med. 2025;8:174.
    

    >> Share

    
    

    
    Orphanet J Rare Dis

56. AFZAL A, Liu YY, Noureen A, Rehman A, et al
    Epidemiology of gall bladder cancer and its prevalence worldwide: a meta-analysis.
    Orphanet J Rare Dis. 2025;20:143.
    

    >> Share

    
    

    
    Pan Afr Med J

57. ZIANI I, Ibrahimi A, Nouini Y
    Ureterocele with embedded stone suggesting a diagnosis of bladder tumor: beware of the diagnostic trap! (case report and literature review).
    Pan Afr Med J. 2024;49:119.
    

    >> Share

    
    

    
    Pharmacoeconomics

58. MANDRIK O, Thomas C, Akpan E, Catto JWF, et al
    Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness.
    Pharmacoeconomics. 2025;43:441-452.
    

    >> Share

    
    

    
    Scand J Urol

59. ULLEN A, Aljabery F, Dahlman P, Falkman K, et al
    Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease.
    Scand J Urol. 2025;60:76-82.
    

    >> Share

    
    

    
    Sci Rep

60. XU H, Zhang Y, Zhang Z, Wang J, et al
    Development and validation of a nomogram for predicting prostatic urethral involvement in bladder cancer.
    Sci Rep. 2025;15:10431.
    

    >> Share

    
    
61. CAI L, Yang X, Yu J, Shao Q, et al
    Deep learning on T2WI to predict the muscle-invasive bladder cancer: a multi-center clinical study.
    Sci Rep. 2025;15:9942.
    

    >> Share

    
    

    
    STAR Protoc

62. MAO W, Zhang H, Ji J, Wu J, et al
    Protocol for single-cell RNA sequencing and spatial transcriptomics of bladder Ewing sarcoma.
    STAR Protoc. 2025;6:103687.
    

    >> Share

    
    

    
    Surg Infect (Larchmt)

63. BOURGI A, Ghanem O, Brocail C, Bruyere F, et al
    Is There Always a Need to Perform Urine Culture before Bacillus Calmette-Guerin Instillation for Bladder Cancer?
    Surg Infect (Larchmt). 2025 Mar 24:0. doi: 10.1089/sur.2024.
    

    >> Share

    
    

    
    Transl Oncol

64. WU Y, Xu Z, Wang R, Bai Y, et al
    Prognostic biomarker PSMD14 facilitates bladder cancer tumorigenesis and progression by regulating Nucleolin-YAP1 axis.
    Transl Oncol. 2025;55:102370.
    

    >> Share

    
    

    
    Urology

65. WILLIAMS SB, Yapici HO, Singhal PK, Weimer I, et al
    Real-World Economic Burden and Healthcare Resource Utilization of Radical Cystectomy and Trimodal Therapy for Bladder Cancer in the United States.
    Urology. 2025 Mar 21:S0090-4295(25)00280-8. doi: 10.1016/j.urology.2025.
    

    >> Share

    
    
66. MALSHY K, Bandari J, Cheng Z, Kadambi S, et al
    Tailoring Cystoscopy Surveillance: Addressing the Needs of Frail Bladder Cancer Patients.
    Urology. 2025 Mar 21:S0090-4295(25)00253-5. doi: 10.1016/j.urology.2025.
    

    >> Share

    
    
67. SADE JP, Ferraris F, Raman J
    The (Re) evolution in the treatment of bladder cancer.
    Urology. 2025 Mar 21:S0090-4295(25)00287-0. doi: 10.1016/j.urology.2025.
    

    >> Share

    
    

    
    World J Urol

68. MANCON S, Soria F, Hurle R, Enikeev D, et al
    Association of energy source with outcomes in en bloc TURB: secondary analysis of a randomized trial.
    World J Urol. 2025;43:191.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share